Novavax to Participate at Two Upcoming Investor Conferences
28 Agosto 2018 - 5:05PM
Novavax to Participate at Two Upcoming Investor Conferences
Novavax, Inc. (NASDAQ: NVAX) today announced that Novavax will
participate in the B. Riley FBR Annual Healthcare Conference and
the Citi 13th Annual Biotech Conference in September.
Conference details are as follows:
B. Riley
FBR Annual Healthcare Conference |
|
Title: |
“Vaccine & Antibiotics
Can’t Be Developed For Some Intractable Infectious
Diseases” |
Date and
Time: |
Tuesday, September 4, 1:55 –
2:55 p.m. |
Moderator: |
George Zavoico, B. Riley
FBR |
Panelists: |
Vivek Shinde, M.D., Ph.D.,
Director of Clinical Development, Novavax |
|
Robert Stein, M.D., Ph.D.,
Senior R&D Advisor, Agenus |
Location: |
New York Marriott East
Side |
|
Citi 13th Annual Biotech
Conference |
|
Date: |
Thursday, September 6 |
Forum: |
Investor meetings |
Location: |
Four Seasons Hotel Boston |
About Novavax
Novavax, Inc. (NASDAQ:NVAX) is a late-stage
biotechnology company that drives improved health globally through
the discovery and development of innovative vaccines to prevent
serious respiratory diseases. ResVax, its RSV vaccine for infants
via maternal immunization, is the only vaccine in a Phase 3
clinical program and is poised to help prevent the second leading
cause of death in children under one year of age worldwide. Novavax
is also advancing the clinical study of our influenza nanoparticle
vaccine, which addresses key factors that lead to poor efficacy by
currently approved flu vaccines. Novavax is a leading innovator of
recombinant vaccines; its proprietary recombinant technology
platform combines the power and speed of genetic engineering to
efficiently produce a new class of highly immunogenic particles
addressing urgent global health needs.
For more information, visit www.novavax.com and
connect with us on Twitter and LinkedIn.
Contact:
InvestorsNovavax, Inc.Erika TrahanSenior Manager, Investor &
Public Relationsir@novavax.com240-268-2000
Westwicke PartnersJohn
Woolfordjohn.woolford@westwicke.com443-213-0506
MediaSam BrownMike Beyermikebeyer@sambrown.com312-961-2502
Novavax (NASDAQ:NVAX)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novavax (NASDAQ:NVAX)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024